(4S,4'S)-2,2'-(Cyclopentane-1,1-diyl)bis(4-isopropyl-4,5-dihydrooxazole)

Catalog No. :
ACXFRM014
CAS No. :
1379452-52-4
Molecular Formula :
C17H28N2O2
Molecular Weight :
292.42

IUPAC Name:(4S,4'S)-2,2'-(cyclopentane-1,1-diyl)bis(4-isopropyl-4,5-dihydrooxazole)

(4S,4'S)-2,2'-(Cyclopentane-1,1-diyl)bis(4-isopropyl-4,5-dihydrooxazole) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$50.00Login to see priceIn stockInquiry
100mg97%$65.00Login to see priceIn stockInquiry
250mg97%$149.00Login to see priceIn stockInquiry
1g97%$376.00Login to see priceIn stockInquiry
5g97%$1502.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4S,4'S)-2,2'-(Cyclopentane-1,1-diyl)bis(4-isopropyl-4,5-dihydrooxazole)
IUPAC Name(4S,4'S)-2,2'-(cyclopentane-1,1-diyl)bis(4-isopropyl-4,5-dihydrooxazole)
MDL No.MFCD24849484
Molecular FormulaC17H28N2O2
Molecular Weight292.42
SMILESCC([C@@H]1N=C(C2(C3=N[C@@H](C(C)C)CO3)CCCC2)OC1)C
InChI KeyVZFCYSTXXNIPPR-ZIAGYGMSSA-N
Synonym(4S,4'S)-2,2'-(Cyclopentane-1,1-diyl)bis(4-isopropyl-4,5-dihydrooxazole)
CAS No.1379452-52-4
PubChem CID60149608

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACXFRM014 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXFRM014 route product structure diagram
    ACXFRM0141379452-52-4 In Stock
Inquiry

2. ACXFRM014 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXFRM014 route product structure diagram
    ACXFRM0141379452-52-4 In Stock
Inquiry

Comments (0)